China Pharma Holdings, Inc. CPHI
At closeNov 3, 2026, 5:51 PM EST
After hours · Nov 3, 5:51 PM ET
- YTD
- -49.65%
- 1 year
- -62.63%
- Market cap
- 26.21M
- Revenue (ttm)
- 6.25M
- Profit margin
- -70.48%
- EPS (ttm)
- -0.42
- Shares out
- 19.25M
- YTD return
- -49.65%
- 1-year return
- -62.63%
- Volume
- 71.42K
- Avg volume
- 1.88M
- Open
- 0.6184
- Previous close
- 0.6063
- Day's range
- 0.584 – 0.6354
- 52-week range
- 0.38 – 19.19
- Beta
- 0.71
2Y -1.9908 (-76.57%)
Key statistics
- Enterprise value
- 6.68M
- PEG ratio
- 0.00
- Price / sales
- 0.55
- Price / book
- 0.26
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -15.80%
- Free cash flow
- 669.60K
- Total cash
- 739.34K
- Total debt
- 4.06M
- Return on equity
- -74.89%
- Short % of float
- 1.22%
- 50-day average
- 0.214
- 200-day average
- 0.2588
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -0.06 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.09 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.07 | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -0.30 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -0.30 | — | — |
| May 12, 2023 | Mar 1, 2023 | 0.00 | -0.30 | — | — |
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- China
- Website
- chinapharmaholdings.com
News
12 Health Care Stocks Moving In Monday's After-Market Session 
12 Health Care Stocks Moving In Thursday's Pre-Market Session - 12 Health Care Stocks Moving In Wednesday's After-Market Session
Thermo Fisher Scientific Showcases New Solutions and Expanded Capabilities to Accelerate Drug Development at CPHI Milan 2026 
Lifecore Biomedical to Participate at CPHI Global Conference 
China Pharma Holdings, Inc. Announces Closing of $5.0 Million Registered Direct Offering - 12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's Intraday Session 
Crude Oil Gains 2%; GE Vernova Shares Fall After Q2 Earnings 
Nasdaq Down Over 100 Points; AT&T Shares Gain After Upbeat Earnings
Your note
Sign in to keep a note on CPHI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| LI ZHILIN | Chief Executive Officer | Stock Award(Grant) | Sep 28, 2023 | 15,138,100 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Xtx Topco Ltd | 0.11% | 21,587 | 3.88K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.10% | 19,047 | 3.43K | Sep 29, 2024 |
| First Community Trust Na | 0.00% | 30 | 5 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.04% | 14,500 | 2.61K | Jun 29, 2023 |